PR Newswire Clinical TrialsOriginal article
Pivotal SPRAY-CB Trial of RejuvenAir® Published in American Journal of Respiratory and Critical Care Medicine
Data ReadoutpositiveRejuvenAir®Positive
AI Analysis
Summary
CSA Medical's pivotal SPRAY-CB trial of RejuvenAir® demonstrated clinically meaningful improvements in COPD quality of life and symptoms with a 38.4% relative reduction in severe exacerbation rates in a randomized, blinded, sham-controlled study, with results published in the American Journal of Respiratory and Critical Care Medicine.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Randomized, blinded, sham-controlled pivotal trial (SPRAY-CB) demonstrated clinically meaningful improvements in quality of life and COPD symptoms with 38.4% relative reduction in severe exacerbation rates
Importance:7/10
Sentiment:
0.85
COPDmedical devicepivotal trialclinical dataquality of lifeexacerbation reduction
Read the original article
Published by PR Newswire Clinical Trials on September 23, 2026 11:00 AM